Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT05740111

The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals

The PREPAIRD Study: Personalized suRveillance for Early Detection and Prevention of Pancreatic cAncer in High Risk inDividuals

Status
Enrolling By Invitation
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
Oslo University Hospital · Academic / Other
Sex
All
Age
30 Years – 80 Years
Healthy volunteers
Accepted

Summary

The objective of this national and multidisciplinary project is to establish and evaluate a personalized surveillance program (SP) for early diagnosis of pancreatic cancer (PC) and its precursors in individuals with a hereditary predisposition to the disease (High RIsk Individuals (HRI)). Patients who either carry a germline mutation in a PC susceptibility gene (CDKN2A, STK11, TP53, PRSS1), or have a strong family history of PC, will be enrolled through their genetics clinic at the university hospitals in Oslo, Bergen, Trondheim and Tromsø. Surveillance consists of annual MRI, assessment of blood glucose and lipid levels, new onset diabetes (NOD) and unintentional weight loss. Blood samples will be drawn for ctDNA-analysis (circulating tumor DNA) and the IMMrayTM PanCan-d test (a novel microarray-based diagnostic test for PC) at baseline and in those who develop lesions. The psychological burden and cost-benefit of the SP will be analyzed. The study addresses an unmet need for the care of HRI in Norway, and is expected to improve PC prognosis. It will be the first to provide evidence on the combined value of a panel of blood-borne biomarkers in surveillance, and provide morphological and molecular data on PC and (non)-neoplastic pancreatic changes in HRI.

Conditions

Interventions

TypeNameDescription
OTHERAnnual surveillanceAnnual surveillance includes annual MRI and/or an assessment new onset diabetes and unintended weight loss.

Timeline

Start date
2022-09-01
Primary completion
2042-12-31
Completion
2042-12-31
First posted
2023-02-22
Last updated
2023-02-22

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT05740111. Inclusion in this directory is not an endorsement.